knowledge -WSS

knowledge

author：explore 2025-09-30 08:53:06 - browse：64659

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： NIH fellows want a pay raise. Will that mean less money for grants?

hotspot

WSS

Elizabeth Holmes on track for early release from her 11

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

Lecanemab for Alzheimer's is coming. Is the health system ready?

Why ADHD is under

Heart disease in astronauts blamed on cosmic radiation

HCA discloses massive data breach affecting 11 million patients

Wikipedia

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

Hollywood unions extend contract negotiations for actors

Alnylam reports growth in sales of rare disease treatments

Malaria cases in Florida and Texas: Here’s what you need to know

Personalized medicine goes far beyond genetics

Medicare details structure of new drug price negotiation program

Why 40% Americans with Parkinson’s don’t see a neurologist

Medical records are filled with copy

NIH fellows want a pay raise. Will that mean less money for grants?

Medical records are filled with copy

Group behind ProMed defends move to subscription

explore

Biden launches a new push to limit health care costs

New research casts further doubt on a common procedure used with IVF

A new study sees potential in DNA sequencing of infants

California’s proposed $25 per hour health care minimum wage

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

Petition to FDA: Get the lead out of consumer hair dyes

knowledge

hotspot

hotspot

leisure time